文献速递慢性静脉疾病

Flebogrif机械化学腔内消融治疗静脉曲张的系统评价与Meta分析

A systematic review and meta-analysis of mechanochemical endovenous ablation using Flebogrif for varicose veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-06-06

该系统评价与Meta分析纳入5篇文献、392例患者共348次手术,评估Flebogrif机械化学消融治疗大隐静脉功能不全的疗效与安全性。汇总3个月解剖成功率为95.6%(95%CI 93.2%-98.0%),12个月为93.2%(95%CI 90.3%-96.1%);3个月内深静脉血栓发生率为0.3%,血栓性浅静脉炎为13.3%-14.5%,色素沉着为3.3%-10.0%。作者认为该技术安全、耐受性好,但需更高质量研究与其他腔内治疗方式比较。

要点

  • Flebogrif机械化学消融3个月解剖成功率达95.6%,12个月为93.2%。
  • 3个月内深静脉血栓发生率仅0.3%,血栓性浅静脉炎为13.3%-14.5%。
  • 纳入研究方法学质量中等,尚需大样本高质量研究与其他腔内治疗比较。

核心结论

  • Flebogrif机械化学消融治疗大隐静脉功能不全是安全且耐受性良好的手术方式。
  • 仍需设计良好、样本量充足且随访充分的研究,比较其与其他腔内治疗方式的有效性,并明确Flebogrif的确定地位。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、Embase和Cochrane Library。
  • 纳入标准为使用Flebogrif治疗隐静脉功能不全、英文发表且有全文可获取的研究。
  • 共纳入5篇文章,报告392例患者的348次手术。
  • 采用非随机研究方法学指数(MINORS)评估方法学质量,采用随机效应模型估计解剖成功率。

主要发现

  • 4项研究报告3个月解剖成功,3项研究报告12个月解剖成功。
  • 汇总3个月解剖成功率为95.6%(95%CI,93.2%-98.0%)。
  • 12个月解剖成功率为93.2%(95%CI,90.3%-96.1%)。
  • 3个月内唯一报告的主要并发症为深静脉血栓,发生率为0.3%。
  • 3个月内血栓性浅静脉炎发生率为13.3%-14.5%,色素沉着为3.3%-10.0%。

临床怎么用

  • 对于隐静脉功能不全患者,Flebogrif机械化学消融可作为安全、耐受性好的腔内治疗选择。
  • 术中及术后需关注深静脉血栓和血栓性浅静脉炎等并发症的发生。
  • 因缺乏与其他腔内治疗方式的头对头比较,选择该器械时应结合患者具体情况与现有证据水平综合判断。

局限性

  • 纳入研究的方法学质量仅为中等。
  • 缺乏与其他腔内治疗方式的有效性比较。
  • 需要设计良好、样本量充足且随访充分的研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the present study, we reviewed and analyzed the currently available data on the Flebogrif device (Balton, Warsaw, Poland) to define its role in the global varicose vein treatment devices market. METHODS: A systematic literature search was performed in MEDLINE, Embase, and the Cochrane Library. Studies were eligible if they had included patients treated using the Flebogrif for saphenous vein incompetence, had been reported in English, and had the full text available. The methodologic quality of the studies was assessed using the methodologic index for nonrandomized studies (MINORS) score. A random effects model was used to estimate the primary outcome of anatomic success, defined as the occlusion rate of the treated vein. The estimates are reported with the 95% confidence intervals (CIs). The secondary outcomes were clinical success, complication rate, pain during and after the procedure, and time to return to work. RESULTS: Five articles met the inclusion criteria, reporting 348 procedures in 392 patients. Four studies reported the 3-month anatomic success, and three studies reported the 12-month anatomic success. The pooled 3-month anatomic success rate was 95.6% (95% CI, 93.2%-98.0%). The 12-month anatomic success rate was 93.2% (95% CI, 90.3%-96.1%). The only major complication reported within 3 months was deep vein thrombosis, which developed in 0.3% of the patients. The minor complications of thrombophlebitis and hyperpigmentation had occurred in 13.3% to 14.5% and 3.3% to 10.0% of patients, respectively, within 3 months. The methodologic quality of the included studies was moderate. CONCLUSIONS: Mechanochemical ablation using the Flebogrif device is a safe and well-tolerated procedure for the treatment of saphenous vein insufficiency. However, well-designed studies of sufficient sample size and follow-up are required to compare the effectiveness with other endovenous treatment modalities and define the definitive role of the Flebogrif device.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Alozai T, Huizing E, Schreve M, et al. A systematic review and meta-analysis of mechanochemical endovenous ablation using Flebogrif for varicose veins. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34091106. doi:10.1016/j.jvsv.2021.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。